News | November 07, 2022
Rossari Biotech Q2 FY23 revenue up 11%; Profit down 9%
H1 FY23 revenues at Rs. 860.1 crore, higher by 40% YoY whereas PAT at Rs. 52.6 crore, higher by 4% YoY
H1 FY23 revenues at Rs. 860.1 crore, higher by 40% YoY whereas PAT at Rs. 52.6 crore, higher by 4% YoY
The voluntary program is the first time the FDA will allow excipient manufacturers to obtain review of certain novel excipients prior to their use in drug formulations.
NFIL’s ambition is to reach revenues of US$100mn from CDMO by FY25.
DKSH has signed an agreement to acquire two ear care brands from Noru Pharma for Australia, New Zealand, and selected markets in Asia.
New material distribution will serve medical device and pharmaceutical packaging manufacturers.
Dr. Reddy’s largest manufacturing facility in Bachupally, Hyderabad, joins Global Lighthouse Network of the World Economic Forum
The certification will open new avenues for our flagship brand “Dr Trust”, enabling them to export these devices to many more countries
The company increases its efficiency and is able to face the growing demand for its services.
DSCO has requested WHO to share at the earliest with CDSCO the report on establishment of causal relation to death with the medical products in question etc.
The inspection concluded with no observation (FDA-483) issued.
Subscribe To Our Newsletter & Stay Updated
